Business Description
![Evotec SE Evotec SE logo](https://static.gurufocus.com/logos/0C000008RR.png?14)
Evotec SE
ISIN : DE0005664809
Compare
Compare
Traded in other countries / regions
EVT.Germany0IRF.UKEVO.USA1EVT.ItalyEVT.BulgariaEVT.Austria IPO Date
2021-07-05Description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.83 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.57 | |||||
Debt-to-EBITDA | -7.03 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 0.92 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.7 | |||||
3-Year EBITDA Growth Rate | -38.6 | |||||
3-Year FCF Growth Rate | -42.2 | |||||
3-Year Book Growth Rate | 12.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 16 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 82.48 | |||||
9-Day RSI | 71.71 | |||||
14-Day RSI | 70.54 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.86 | |||||
Quick Ratio | 1.79 | |||||
Cash Ratio | 1.17 | |||||
Days Inventory | 18.73 | |||||
Days Sales Outstanding | 64.71 | |||||
Days Payable | 64.21 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | -8.13 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 20.16 | |||||
Operating Margin % | -10.09 | |||||
Net Margin % | -11.68 | |||||
FCF Margin % | -28.96 | |||||
ROE % | -7.99 | |||||
ROA % | -4.02 | |||||
ROIC % | -4.2 | |||||
ROC (Joel Greenblatt) % | -11.45 | |||||
ROCE % | -4.97 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 192.31 | |||||
Shiller PE Ratio | 57.36 | |||||
PS Ratio | 1.9 | |||||
PB Ratio | 1.34 | |||||
Price-to-Tangible-Book | 1.82 | |||||
EV-to-EBIT | -17.78 | |||||
EV-to-Forward-EBIT | 64.73 | |||||
EV-to-EBITDA | -17.78 | |||||
EV-to-Forward-EBITDA | 13.47 | |||||
EV-to-Revenue | 2.04 | |||||
EV-to-Forward-Revenue | 1.74 | |||||
EV-to-FCF | -7.07 | |||||
Price-to-Projected-FCF | 2.55 | |||||
Price-to-Median-PS-Value | 0.28 | |||||
Earnings Yield (Greenblatt) % | -5.62 | |||||
FCF Yield % | -15.19 | |||||
Forward Rate of Return (Yacktman) % | 23.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evotec SE Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil лв) | 1,535.674 | ||
EPS (TTM) (лв) | -1.004 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 70.54 | ||
14-Day ATR (лв) | 0.11607 | ||
20-Day SMA (лв) | 10.09 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (лв) | 8.8 - 10.17 | ||
Shares Outstanding (Mil) | 177.19 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Evotec SE Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Evotec SE Stock Events
Event | Date | Price(лв) | ||
---|---|---|---|---|
No Event Data |
Evotec SE Frequently Asked Questions
What is Evotec SE(XBUL:EVT)'s stock price today?
The current price of XBUL:EVT is лв10.09. The 52 week high of XBUL:EVT is лв10.17 and 52 week low is лв8.80.
When is next earnings date of Evotec SE(XBUL:EVT)?
The next earnings date of Evotec SE(XBUL:EVT) is 2024-08-29 Est..
Does Evotec SE(XBUL:EVT) pay dividends? If so, how much?
Evotec SE(XBUL:EVT) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |